China's Second-largest CRO Seeks Initial Public Offering In The U.S.
Shanghai-based ShangPharma hopes to capitalize on a growing wave of outsourcing by biopharmaceutical developers looking to reduce costs and spread risk in the wake of an R&D productivity slump.
More from China
More from Asia
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.